Committee for Advanced Therapies
E23508
The Committee for Advanced Therapies is a scientific body within the European Medicines Agency responsible for evaluating and providing expert opinions on advanced therapy medicinal products such as gene, cell, and tissue-engineered therapies.
All labels observed (2)
| Label | Occurrences |
|---|---|
| Committee for Advanced Therapies canonical | 3 |
| https://www.ema.europa.eu/en/committees/committee-advanced-therapies-cat | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T184505 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Committee for Advanced Therapies Context triple: [European Medicines Agency, hasCommittee, Committee for Advanced Therapies]
-
A.
Banting Research Foundation
The Banting Research Foundation is a Canadian organization that funds early-career health and biomedical researchers, established to honor and continue the scientific legacy of insulin co-discoverer Sir Frederick Banting.
-
B.
National Center for Advancing Translational Sciences
The National Center for Advancing Translational Sciences is a U.S. biomedical research center focused on accelerating the development and delivery of new diagnostics, treatments, and cures by improving the translational science process.
-
C.
Center for Scientific Review
The Center for Scientific Review is the National Institutes of Health component responsible for overseeing the peer review of most grant applications to ensure scientific merit and integrity in funding decisions.
-
D.
National Human Genome Research Institute
The National Human Genome Research Institute is a U.S. government biomedical research organization that leads and funds research on the structure, function, and impact of the human genome.
-
E.
Wistar Institute
The Wistar Institute is a renowned biomedical research center in Philadelphia known for its pioneering work in cancer, immunology, and vaccine development.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Committee for Advanced Therapies Target entity description: The Committee for Advanced Therapies is a scientific body within the European Medicines Agency responsible for evaluating and providing expert opinions on advanced therapy medicinal products such as gene, cell, and tissue-engineered therapies.
-
A.
Banting Research Foundation
The Banting Research Foundation is a Canadian organization that funds early-career health and biomedical researchers, established to honor and continue the scientific legacy of insulin co-discoverer Sir Frederick Banting.
-
B.
National Center for Advancing Translational Sciences
The National Center for Advancing Translational Sciences is a U.S. biomedical research center focused on accelerating the development and delivery of new diagnostics, treatments, and cures by improving the translational science process.
-
C.
Center for Scientific Review
The Center for Scientific Review is the National Institutes of Health component responsible for overseeing the peer review of most grant applications to ensure scientific merit and integrity in funding decisions.
-
D.
National Human Genome Research Institute
The National Human Genome Research Institute is a U.S. government biomedical research organization that leads and funds research on the structure, function, and impact of the human genome.
-
E.
Wistar Institute
The Wistar Institute is a renowned biomedical research center in Philadelphia known for its pioneering work in cancer, immunology, and vaccine development.
- F. None of above. chosen
Statements (43)
| Predicate | Object |
|---|---|
| instanceOf |
committee of the European Medicines Agency
ⓘ
regulatory body ⓘ scientific committee ⓘ |
| abbreviation | CAT ⓘ |
| composition |
experts in cell therapy
ⓘ
experts in gene therapy ⓘ experts in tissue engineering ⓘ healthcare professional representatives ⓘ patient representatives ⓘ |
| country | European Union ⓘ |
| field |
advanced therapy medicinal products
ⓘ
medicine ⓘ pharmacology ⓘ regulatory science ⓘ |
| goal |
ensure that advanced therapy medicinal products are safe, effective and of high quality
ⓘ
facilitate patient access to innovative advanced therapies in the EU ⓘ |
| jurisdiction | European Union ⓘ |
| language | English ⓘ |
| legalBasis | Regulation (EC) No 1394/2007 ⓘ |
| location |
Amsterdam
ⓘ
Netherlands ⓘ |
| parentOrganization | European Medicines Agency ⓘ |
| partOf | European Medicines Agency ⓘ |
| productTypeEvaluated |
combined advanced therapy medicinal products
ⓘ
gene therapy medicinal products ⓘ somatic cell therapy medicinal products ⓘ tissue engineered products ⓘ |
| regionServed | European Economic Area ⓘ |
| regulatoryScope |
classification of advanced therapy medicinal products
ⓘ
evaluation of marketing authorisation applications for advanced therapies ⓘ follow-up of authorised advanced therapy medicinal products ⓘ scientific advice on advanced therapy development ⓘ |
| role |
advise other EMA committees on advanced therapies
ⓘ
contribute to development of guidelines for advanced therapies ⓘ evaluate advanced therapy medicinal products ⓘ provide scientific opinions on advanced therapy medicinal products ⓘ support innovation in advanced therapies while ensuring patient safety ⓘ |
| sector |
pharmaceutical regulation
ⓘ
public health ⓘ |
| supervisingBody | Management Board of the European Medicines Agency ⓘ |
| website |
Committee for Advanced Therapies
self-linksurface differs
ⓘ
surface form:
https://www.ema.europa.eu/en/committees/committee-advanced-therapies-cat
|
| worksWith |
Committee for Medicinal Products for Human Use
ⓘ
Pharmacovigilance Risk Assessment Committee ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Committee for Advanced Therapies Description of subject: The Committee for Advanced Therapies is a scientific body within the European Medicines Agency responsible for evaluating and providing expert opinions on advanced therapy medicinal products such as gene, cell, and tissue-engineered therapies.
Referenced by (4)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject surface form:
European Medicines Agency
Committee for Advanced Therapies
→
website
→
Committee for Advanced Therapies
self-linksurface differs
ⓘ
this entity surface form:
https://www.ema.europa.eu/en/committees/committee-advanced-therapies-cat